摘要
目的:比较肠炎康联合美沙拉嗪与美沙拉嗪治疗溃疡性结肠炎的疗效,为临床治疗溃疡性结肠炎提供合理用药的建议。方法:将吉林大学第一医院2010年6月-2011年5月门诊收治的溃疡性结肠炎患者90例,随机分为治疗组45例和对照组45例,分别接受肠炎康联合美沙拉嗪与美沙拉嗪的治疗方法,用药后对两组的治疗有效率、结肠镜下形态变化及C-反应蛋白及血沉等进行比较,评价其疗效及安全性。结果:两组治疗后的有效率、结肠镜下形态变化比较均具有统计学意义(P<0.05)。结论:肠炎康联合美沙拉嗪的疗效优于美沙拉嗪,值得临床推广应用。
Objective：Compare the proposed traditional prescription joint metalizing and mesalazine treatment the curative effect of ulcerative colitis,provide rational drug use advice for clinical treatment of ulcerative colitis.Method： Ninty cases of ulcerative colitis patients in our hospital from June 2010 to May 2011,randomly divided into treatment group（45 cases） and control group（45 cases）,were given the proposed traditional prescription joint mesalazine and mesalazine treatment respectively.After that,compare with two groups of treatment effective rate,under colonoscopy form change,C-reactive protein（CRP）,ergthrocyte sedimentration rate（ESR） etc,evaluate its effectiveness and safety.Result： The treatment effective rate and under colonoscopy form change of the two groups after treatment are all have statistical significance（P＆lt;0.05）.Conclusion： The curative effect of the proposed traditional prescription joint mesalazine is better than that of mesalazine.It is worthy of clinical application.
出处
《中国实验方剂学杂志》
CAS
北大核心
2013年第9期323-325,共3页
Chinese Journal of Experimental Traditional Medical Formulae
关键词
肠炎康
自拟中药方
美沙拉嗪
溃疡性结肠炎
结肠镜
C-反应蛋白
血沉
changyankang
proposed traditional prescription
mesalazine
ulcerative colitis
C-reactive protein
ergthrocyte sedimentration rate
